Osaka, Japan

Kousuke Tani

This inventor holds 33 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 8 EPO patents. Top assignees: Ono Pharmaceutical Co., Ltd., Ono Pharmaceuticals Co., Ltd., Ono Pharmaceuticalco.,ltd.. Active years: 2000-2025.

USPTO Granted Patents = 33 

% Patents Active = 60.6

 

 

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 284(Granted Patents)


Location History:

  • Mishima-gun, JP (2001 - 2011)
  • Osaka, JP (2000 - 2023)

Company Filing History:


Years Active: 2000-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Tricyclic Spiro Compound
Bicyclic Compound
EP4 Antagonist
EP2 Agonist Activity
ALXR Agonist Compound
8-Azaprostaglandin Derivative
Medicinal Composition
Carboxylic Acid Derivatives
Benzoic Acid Derivatives
Cycloalkyl-Prostaglandin Derivatives
Pharmaceutical Agents
Medical Applications
33 patents (USPTO):Explore Patents

Title: The Innovative Journey of Kousuke Tani

Introduction: Kousuke Tani, a pioneering inventor hailing from Osaka, Japan, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Tani's latest patents focus on advancements in artificial intelligence and robotics, showcasing his commitment to pushing the boundaries of technological possibilities.

Career Highlights: With a career spanning over two decades, Tani has established himself as a leading figure in the tech industry, known for his out-of-the-box thinking and inventive solutions to complex problems.

Collaborations: Throughout his career, Tani has collaborated with top research institutions and leading tech companies to bring his ideas to life, fostering a culture of innovation and creativity in the industry.

Conclusion: Kousuke Tani's relentless pursuit of innovation and his passion for creating cutting-edge technologies continue to inspire the next generation of inventors and shape the future of the tech landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…